Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Conventional vaccine platforms like mRNA face limitations in safety and durability for complex challenges such as cancer.
• Extracellular vesicles (EVs) are emerging as a next-generation vaccine platform due to their endogenous origin and immune-modulating properties.

Purpose of the Study:

• To review the progress in extracellular vesicle (EV)-based cancer vaccine development.
• To highlight the potential of EVs as a safer, more precise, and broadly applicable immunotherapy platform.

Main Methods:

• Review of recent advancements in EV biogenesis and engineering strategies for vaccine design.
• Analysis of preclinical and clinical evidence for EV-based cancer vaccines.
• Discussion of strategies for antigen loading, surface modification, and cytokine modulation of EVs.

Main Results:

• EVs can be engineered for modular vaccine design, integrating antigen delivery, immune activation, and adjuvant functions.
• Different cellular sources of EVs (dendritic cells, macrophages, lymphocytes, tumor cells) yield distinct immunological properties.
• Emerging evidence supports the translational potential of EV-based cancer vaccines.

Conclusions:

• EV-based vaccines represent a promising next-generation platform for immunotherapy, especially in oncology.
• Key challenges including vesicle heterogeneity and manufacturing standardization need to be addressed for clinical advancement.